HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (4'- (5- methylhexahydropyrrolo(3,4- b)pyrrol- 1- yl)biphenyl- 4- yl)- 2H- pyridazin- 3- one

a histamine H3 receptor antagonist; structure in first source

Also Known As:

ABT-288

Networked: 4 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - 2-(4'-(5-methylhexahydropyrrolo(3,4-b)pyrrol-1-yl)biphenyl-4-yl)-2H-pyridazin-3-one: 4
  - Pyridazines: 11
    - 2-(4'-(5-methylhexahydropyrrolo(3,4-b)pyrrol-1-yl)biphenyl-4-yl)-2H-pyridazin-3-one: 4

Experts

1.	Othman, Ahmed A: 3 articles (11/2014 - 01/2014)
2.	Haig, George M: 2 articles (11/2014 - 01/2014)
3.	Lenz, Robert A: 2 articles (11/2014 - 01/2014)
4.	Bain, Earle: 1 article (11/2014)
5.	Baker, Jeffrey: 1 article (11/2014)
6.	Robieson, Weining: 1 article (11/2014)
7.	Dutta, Sandeep: 1 article (06/2014)
8.	Florian, Hana: 1 article (06/2014)
9.	Gertsik, Lev: 1 article (06/2014)
10.	Haig, George: 1 article (06/2014)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 11/01/2014 - "Neither dose of ABT-288 resulted in cognitive improvement in clinically stable adults with schizophrenia." 06/01/2014 - "This study characterized the safety, tolerability and pharmacokinetics of ABT-288 in stable subjects with schizophrenia. " 11/01/2014 - "ABT-288 is a highly potent histamine-3 receptor antagonist that has demonstrated pro-cognitive effects in preclinical models relevant to schizophrenia. " 06/01/2014 - "ABT-288 was tolerated at a 15-fold higher dose and 12-fold higher exposures in subjects with schizophrenia than previously observed in healthy volunteers. " 06/01/2014 - "At comparable multiple doses, ABT-288 exposure in subjects with schizophrenia was 45% lower than that previously observed in healthy subjects. "
2.	Cognitive Dysfunction 11/01/2014 - "This study evaluated the efficacy and safety of two doses of ABT-288 in the treatment of cognitive impairment associated with schizophrenia. " 11/01/2014 - "A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia." 01/01/2011 - "A number of H(3) antagonists, including 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride (BF2.649), (1R,3R)-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746), 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254), MK-0249 (structure not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not yet disclosed), have advanced to the clinical area for the potential treatment of human cognitive disorders. "
3.	Psychotic Disorders (Schizoaffective Disorder) 11/01/2014 - "Overall, study medication was tolerated; however, an increased incidence of psychosis-related and sleep-related adverse events was associated with ABT-288. "
4.	Dementia (Dementias) 01/01/2014 - "A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia." 01/01/2014 - "ABT-288 did not demonstrate efficacy in the symptomatic treatment of Alzheimer's dementia." 01/01/2014 - "Evaluate the efficacy and safety of ABT-288 in subjects with mild-to-moderate Alzheimer's dementia. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Niacinamide (Nicotinamide)
3.	MK-0249
4.	6- ((3- cyclobutyl- 2,3,4,5- tetrahydro- 1H- 3- benzazepin- 7- yl)oxy)- N- methyl- 3- pyridinecarboxamide
5.	pitolisant
6.	piperidine